Zamani, Parvin, Mashreghi, Mohammad, Rezazade Bazaz, Mahere, Zargari, Selma, Alizadeh, Farzaneh, Dorrigiv, Mahyar, Abdoli, Asghar, Aminianfar, Hossein, Hatamipour, Mahdi, Zarqi, Javad, Behboodifar, Saeed, Samsami, Yalda, Khorshid Sokhangouy, Saeideh, Sefidbakht, Yahya, Uskoković, Vuk, Rezayat, Seyed Mahdi, Jaafari, Mahmoud Reza, and Mozaffari-Jovin, Sina
mRNA-lipid nanoparticle (mRNA-LNP) vaccines have proved their efficacy, versatility and unprecedented manufacturing speed during the COVID-19 pandemic. Here we report on the physicochemical properties, thermostability, immunogenicity, and protective efficacy of the nucleoside-modified mRNA-LNP vaccine candidate Iribovax® (also called SNEG2c). Injection of BALB/c mice, rabbits and nonhuman primates with two doses of SNEG2c induced production of high-titers of SARS-CoV-2 spike-specific and receptor-binding domain (RBD)-neutralizing antibodies in immunized animals. In addition to the strong humoral response, SNEG2c elicited substantial Th1-biased T-cell response. Sera from rhesus macaques immunized with a low dose of the vaccine showed robust spike-specific antibody titers 3-24× as high as those in convalescent sera from a panel of COVID-19 patients and 50% virus neutralization geometric mean titer of 1024 against SARS-CoV-2. Strikingly, immunization with SNEG2c completely cleared infectious SARS-CoV-2 from the upper and lower respiratory tracts of challenged macaques and protected them from viral-induced lung and trachea lesions. In contrast, the non-vaccinated macaques developed moderate to severe pulmonary pathology after the viral challenge. We present the results of repeat-dose and local tolerance toxicity and thermostability studies showing how the physicochemical properties of the mRNA-LNPs change over time and demonstrating that SNEG2 is safe, well tolerated and stable for long-term. These results support the planned human trials of SNEG2c. [Display omitted] • Iribovax® is a modified-nucleoside mRNA-lipid nanoparticle vaccine candidate. • Administration of Iribovax® in nonhuman primates induces high titers of neutralizing antibodies. • Iribovax® elicits Th1-biased T cell immunity in mice and clears viral infection in rhesus macaques. • Iribovax® exhibits long-term stability at -20 °C. • Repeat-dose toxicity study demonstrates preclinical safety, supporting the clinical trials. [ABSTRACT FROM AUTHOR]